Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke

PHASE3RecruitingINTERVENTIONAL
Enrollment

596

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

June 30, 2027

Conditions
Stroke, IschemicMedium Vessel Occlusions
Interventions
DRUG

Tenecteplase (0.25mg/kg)

Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).

DRUG

Standard medical treatment

Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.

Trial Locations (7)

100070

NOT_YET_RECRUITING

Beijing tiantan hospital, Beijing

226600

RECRUITING

Hai'an People's Hospital, Nantong

310003

NOT_YET_RECRUITING

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

459000

RECRUITING

Jiyuan Traditional Chinese Medicine Hospital, Jiyuan

472500

RECRUITING

The first people hospital of lingbao, Lingbao

736100

RECRUITING

Jiuquan city people's hospital, Jiuquan

050600

RECRUITING

Xingtang People's Hospital, Shijiazhuang

All Listed Sponsors
collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

Chinese Stroke Association

UNKNOWN

lead

Beijing Tiantan Hospital

OTHER